PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33139291-7	2020	Ceftazidime-avibactam was active against 9.1% of carbapenem-resistant E. coli (63.6% were bla NDM-producers) and 84.6% of K. pneumoniae (74.3% were bla KPC-producers) isolates.	avibactam	12-21	beta-lactamase	Escherichia coli	90-93	
30258039-0	2018	Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype.	avibactam	26-35	beta-lactamase	Escherichia coli	84-87	
30258039-1	2018	A bla KPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent.	avibactam	72-81	beta-lactamase	Escherichia coli	2-5	
30258039-12	2018	We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the bla KPC-2 Omega-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging.	avibactam	68-77	beta-lactamase	Escherichia coli	138-141	
28039278-1	2017	Objectives: Mycobacterium tuberculosis and Mycobacterium abscessus produce broad-spectrum class A beta-lactamases, BlaC and Bla Mab , which are inhibited by clavulanate and avibactam, respectively.	avibactam	173-182	beta-lactamase	Escherichia coli	115-118